Much like Innocan's LPT platform, Doxil is also based on the loading of a drug into liposomes, resulting in better efficacy4. In 2021, Innocan carried out a series experiments of its LPT platform on animals. A one-month long-lasting medication, possible by the LPT platform, would be a major innovation for both animals and humans." This unique liposome platform technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders. https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6043845/ There is no assurance that InnoCan's LPT platform will receive the same degree of success received by Doxil.

Source: Forbes January 20, 2022 09:02 UTC